121 related articles for article (PubMed ID: 38102101)
1. FDA approves new combined treatment for advanced prostate cancer.
Cancer; 2023 Dec; 129(24):3841-3842. PubMed ID: 38102101
[No Abstract] [Full Text] [Related]
2. FDA approves prostate cancer treatment that inhibits testosterone synthesis.
Thompson CA
Am J Health Syst Pharm; 2011 Jun; 68(11):960. PubMed ID: 21593221
[No Abstract] [Full Text] [Related]
3. FDA approves prostate cancer "vaccine".
Tanne JH
BMJ; 2010 May; 340():c2431. PubMed ID: 20442242
[No Abstract] [Full Text] [Related]
4. FDA Approves New
J Nucl Med; 2022 Feb; 63(2):26N. PubMed ID: 35101932
[No Abstract] [Full Text] [Related]
5. FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
Masters SC; Hofling AA; Gorovets A; Marzella L
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):27-28. PubMed ID: 33857629
[No Abstract] [Full Text] [Related]
6. The FDA Approves PSMAtargeted Drug for PET Imaging in Men with Prostate Cancer.
BJU Int; 2021 Mar; 127(3):267-268. PubMed ID: 33630419
[No Abstract] [Full Text] [Related]
7. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
8. FDA approves new agent for the treatment of metastatic prostate cancer.
BJU Int; 2022 Jul; 130(1):3-4. PubMed ID: 35768143
[No Abstract] [Full Text] [Related]
9. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
10. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
11. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
[No Abstract] [Full Text] [Related]
12. FDA approves 11C-choline for PET in prostate cancer.
J Nucl Med; 2012 Dec; 53(12):11N. PubMed ID: 23203247
[No Abstract] [Full Text] [Related]
13. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
14. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
[No Abstract] [Full Text] [Related]
15. New drug approvals for prostate cancer.
Tannock IF
Clin Adv Hematol Oncol; 2024 Jun; 22(5):245-246. PubMed ID: 38805317
[No Abstract] [Full Text] [Related]
16. FDA approves new drug for specific type of advanced breast cancer.
Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
[No Abstract] [Full Text] [Related]
17. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
18. FDA Approves Drug Combo for Kidney Cancer.
Cancer Discov; 2016 Jul; 6(7):687-8. PubMed ID: 27267515
[TBL] [Abstract][Full Text] [Related]
19. Radium - 223 (Xofigo) for prostate cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1426):79-80. PubMed ID: 24081388
[No Abstract] [Full Text] [Related]
20. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
D'Amico AV
J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
